Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) Durvalumab after Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC Jun 23, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) Pooled Analysis Shows Durable Survival With First-Line Nivolumab Plus Ipilimumab in aNSCLC Jun 09, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) AE Burden of Nivolumab-Based IO Therapy in 1L Advanced NSCLC With/Without Chemo Jun 09, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) Lorlatinib Shows Superior Efficacy and Safety Compared to Crizotinib in Advanced ALK-Positive NSCLC Jun 09, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) Pembrolizumab Shows Promise as Adjuvant Therapy in Resected Stage IB-IIIA NSCLC Jun 08, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) Cost-Effectiveness of Adjuvant Atezolizumab in Early-Stage PD-L1 Overexpressing NSCLC Jun 08, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) Durvalumab ± Tremelimumab + Chemo in First-Line Metastatic NSCLC: POSEIDON Study Jun 08, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer) FDA Approval Summary: Nivolumab Plus Chemo for Neoadjuvant Treatment in Resectable NSCLC Jun 08, 2023
